On Monday, Protara Therapeutics Inc (NASDAQ: TARA) opened higher 5.24% from the last session, before settling in for the closing price of $1.91. Price fluctuations for TARA have ranged from $1.04 to $5.24 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 14.22% at the time writing. With a float of $18.41 million, this company’s outstanding shares have now reached $20.63 million.
Let’s look at the performance matrix of the company that is accounted for 27 employees. In terms of profitability, gross margin is 68.54%, operating margin of -3663.33%, and the pretax margin is -3368.29%.
Protara Therapeutics Inc (TARA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Protara Therapeutics Inc is 10.74%, while institutional ownership is 45.32%. The most recent insider transaction that took place on Sep 12 ’24, was worth 215,836. In this transaction 10% Owner of this company sold 126,301 shares at a rate of $1.71, taking the stock ownership to the 45,000 shares. Before that another transaction happened on Sep 11 ’24, when Company’s 10% Owner sold 32,600 for $1.71, making the entire transaction worth $55,880. This insider now owns 51,500 shares in total.
Protara Therapeutics Inc (TARA) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.87 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.98) by 0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.54 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.22% per share during the next fiscal year.
Protara Therapeutics Inc (NASDAQ: TARA) Trading Performance Indicators
Check out the current performance indicators for Protara Therapeutics Inc (TARA). In the past quarter, the stock posted a quick ratio of 16.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.19, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -3.20 in one year’s time.
Technical Analysis of Protara Therapeutics Inc (TARA)
Protara Therapeutics Inc (NASDAQ: TARA) saw its 5-day average volume 0.23 million, a positive change from its year-to-date volume of 0.22 million. As of the previous 9 days, the stock’s Stochastic %D was 75.30%. Additionally, its Average True Range was 0.15.
During the past 100 days, Protara Therapeutics Inc’s (TARA) raw stochastic average was set at 29.54%, which indicates a significant decrease from 69.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.50% in the past 14 days, which was lower than the 56.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9000, while its 200-day Moving Average is $2.6600. Nevertheless, the first resistance level for the watch stands at $2.1800 in the near term. At $2.3400, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.5000. If the price goes on to break the first support level at $1.8600, it is likely to go to the next support level at $1.7000. The third support level lies at $1.5400 if the price breaches the second support level.
Protara Therapeutics Inc (NASDAQ: TARA) Key Stats
There are currently 20,590K shares outstanding in the company with a market cap of 41.47 million. Presently, the company’s annual sales total 0 K according to its annual income of -40,420 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -9,510 K.
